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Abstract
Introduction: Circulating tumor cells (CTCs) reflect aggressive tumor behavior by hematogenous tumor cell
dissemination. The tissue inhibitor of metalloproteinase 1 (TIMP-1) plays a role in tissue invasion and is also
involved in angiogenesis, abrogation of apoptosis and in chemoresistance. Carbonic anhydrase IX (CAIX) is a
metalloenzyme involved in cell adhesion, growth and survival of tumor cells. The aim of the study was to
investigate whether serum concentrations of TIMP-1 and CAIX are associated with the detection of CTC in
metastatic breast cancer.
Methods: Blood was obtained in a prospective multicenter setting from 253 patients with metastatic breast cancer
at the time of disease progression. Serum TIMP-1 and CAIX were determined using commercial ELISA-kits
(Oncogene Science). CTC were detected with the CellSearch™ system (Veridex).
Results: Five or more CTCs were detected in 122 patients out of 245 evaluable patients (49.8%). Out of 253
metastatic patients 70 (28%) had serum TIMP-1 levels above 454 ng/mL. Serum CAIX was elevated above 506 ng/
mL in 90 (35%) patients. Both serum markers had prognostic significance. Median progression free survival (PFS)
was 7.2 months with elevated TIMP-1 vs. 11.4 months with non-elevated levels (p < 0.01). OS was 11.5 vs. 19.1
months (p < 0.01). Median PFS was 7.5 months with elevated CAIX vs. 11.7 months with non-elevated levels (p <
0.01), overall survival (OS) was 13.4 months vs. 19.1 months (p < 0.01). In patients with five or more CTCs, serum
levels were above the cut-off for CAIX in 47% vs. 25% in those with less than five CTCs (p = 0.01). For TIMP-1, 37%
patients with five or more CTCs had elevated serum levels and 17% of patients with less than five CTCs (p = 0.01).
Including TIMP-1, CAIX, CTC and established prognostic factors in the multivariate analysis, the presence of CTCs,
the therapy line and elevated CAIX remained independent predictors of OS.
Conclusions: Elevated serum levels of the invasion markers TIMP-1 and CAIX in metastatic breast cancer are
prognostic markers and are associated with the presence of CTCs. Whether increased secretion of TIMP-1 and/or
CAIX might directly contribute to tumor cell dissemination remains to be elucidated in further investigations.
Trial registration: Current Controlled Trials: ISRCTN59722891
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In breast cancer patients, hematogenous tumor cell dis-
semination is a crucial step in tumor progression and
blood-borne metastases account for the vast majority of
breast cancer-related death. Circulating tumor cells
(CTC) derived from primary tumors and metastatic sites
can be detected in the circulation. Many methods for
the detection of CTC have been described [1,2]. At pre-
sent, the CellSearch
® system, which combines both
automated enrichment and immunostaining, is the only
standardized technology that was approved by the Food
and Drug Administration for the detection of CTC in
patients with metastatic breast, colon, and prostate can-
cer [3-5]. The detection of CTC in blood can provide
prognostic information [3,6]. Moreover, CTC detection
and characterization has already improved our under-
standing of the complex process underlying tumor cell
dissemination and metastatic progression in breast can-
cer. It is widely accepted now that the release of tumor
cells from solid tumors requires specific mechanisms
such as proteolysis and release is enhanced when tumor
hypoxia occurs.
The tissue inhibitor of metalloproteinase 1 (TIMP-1)
i so fi n t e r e s tb e c a u s ei tp l a y sar o l ei nt i s s u ei n v a s i o n
and angiogenesis. A negative prognostic impact of
serum TIMP-1 as well as tissue protein levels was
described in breast cancer, colorectal cancer, and other
malignancies [7-9]. At one side, TIMP-1 inhibits matrix
metalloproteinases (MMPs) and thus, may influence
tumor growth and invasion. On the other side, it has
been demonstrated that TIMP-1 may inhibit apoptosis
in breast epithelial cells [10-12] and promotes cell
growth, tumorigenesis, and angiogenesis in different cell
types, including breast carcinoma cell lines [13-15].
Carbonic anhydrase IX (CAIX) is a metalloenzyme
involved in cell adhesion, growth, and survival of tumor
cells. There is strong evidence that CAIX is involved in
tumor cell proliferation as inhibition of CAIX in vitro
and in vivo significantly reduces growth and survival of
tumor cells [16]. In several epithelial cancers, CAIX
overexpression was shown to be of prognostic relevance
[17-21].
Apart from the cellular transmembrane form of CAIX,
there is a soluble isoform that is released by proteolytic
cleavage and can be detected in peripheral venous blood
[22]. Although several repor t si n d i c a t ear o l eo fs e r u m
CAIX in renal cell cancer [22,23], information about
CAIX in serum of breast cancer patients is limited [24].
In conclusion, several publications demonstrated a
biologic role for TIMP-1 in breast cancer whereas infor-
mation on CAIX is limited. For both markers, experi-
mental and clinical data suggest that they might be also
involved in tumor cell dissemination. However, TIMP-1
and CAIX have so far not been examined in
combination with CTC measurements as a surrogate
marker for hematogenous tumor cell spread. Therefore,
the aim of this study was to investigate the role of
TIMP1 and CAIX serum levels in association with the
presence of CTC in metastatic breast cancer.
Materials and methods
Patients
A total of 254 patients with metastatic breast cancer
from nine German University Breast Cancer Centers
(Düsseldorf (n =4 )E r l a n g e n( n = 30), Essen (n = 46),
Freiburg (n = 9), Hamburg (n = 79), Heidelberg (n =
18), Munich (n = 16), Regensburg (n = 2), and Tübingen
(n = 50)) were enrolled in this prospective, open-label,
non-randomized study. Inclusion criteria were: epithelial
invasive carcinoma of the breast with distant metastatic
disease (M1), age 18 years and older, and first diagnosis
of metastatic disease or disease progression (before start
of new treatment regimen). Patients with a second pri-
mary malignancy (except in situ carcinoma of the cervix
or adequately treated cutaneous basal cell carcinoma)
were excluded. The primary endpoint of the study was
the detection of human epidermal growth factor recep-
tor (HER)2-positive CTC with two different methods
[25].
Blood was drawn before the start of a new line of
therapy. All patients gave their informed consent for the
use of their blood samples. A web-based databank was
designed for data management and on-line documenta-
tion. By the use of this interface, clinical investigators
were blinded for test results and the CTC test sites were
blinded for the clinical data of the patients. The study
was approved by local institutional review boards (Ethics
Board University of Tübingen number 2007/B01) and all
patients gave an informed consent. The trial was regis-
tered in the Current Controlled Trials Registry (no.
ISRCTN59722891).
Patients received systemic therapy according to
national and institutional standards. Response was eval-
uated according to institutional standards usually by
computed tomography (CT) scan every 12 weeks. Med-
ian follow up from the time point of blood sampling
was 11 months (range: 0 to 24 months). At the time of
analysis for this study, 172 patients had progressed and
75 patients had died. Patient characteristics are listed in
Table 1.
Enumeration and characterization of CTC
Detection of CTC was performed with the CellSearch
assay (Veridex LLC, Raritan, NJ, USA) according to the
manufacturers’ instructions without modifications. CTC
analysis by the CellSearch assay was performed by either
of two centers (Institute of Tumor Biology, University
Medical Center, Hamburg-Eppendorf (SR, KP) or
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tests, respectively). These centers have previously con-
ducted a validation study demonstrating that samples
could be stored and transported (up to 72 hours) as
well as examining the high inter- and intra-assay con-
cordance of the results in a multicenter setting [4].
Before the study was started, each breast cancer center
was assigned to send its samples only to the designated
laboratory for the CellSearch assay. Blood samples for
the CellSearch assay were sent at room temperature
based on the manufacturer’s recommendation. All blood
samples were processed within 96 hours for the Cell-
Search assay, or otherwise discarded. The CellSearch
assay was performed by investigators blinded for the
clinical data. 7.5 mL blood samples were collected into
CellSave tubes (Veridex Inc, Raritan, NJ, USA). The
CellSearch Epithelial Cell Test (Veridex Inc, Raritan, NJ,
USA) was applied for CTC enrichment and enumera-
tion. In brief, CTC are captured from peripheral blood
by anti-epithelial cell adhesion molecule-antibody-bear-
ing ferrofluid and subsequently identified by cytokera-
tin-positivity/negativity for the leukocyte common
antigen CD45 and 4’,6-diamidino-2-phenylindole stain-
ing to ensure the integrity of the nucleus. A blood sam-
ple was considered CTC-positive when at least five CTC
were present based on the prognostic relevant cut-off as
previously published [3,6].
Quantitative analysis of serum TIMP-1 levels
Serum TIMP-1 was quantified by commercially available
ELISA (Siemens Healthcare Diagnostics, Tarrytown, NY,
USA). The serum samples and controls were diluted
1:50 with sample diluent buffer (containing bovine
serum albumin, buffer salts and 0.09% sodium azide). A
100 μl volume of the standards, diluted control samples
and diluted serum samples were dispensed into 96-well
plates (coated with an anti-human monoclonal antibody)
and incubated for 30 minutes at room temperature.
Wells were washed and 100 μl of the detection antibody
(containing alkaline phosphatase-labeled anti-TIMP-1
antibody) were added. Plates were incubated for 30 min-
utes at room temperature. After washing, 100 μlo f
chromogenic pNPP-substrate was added for 25 minutes
at room temperature in the dark. The reaction was
stopped with 100 μl of EDTA-stop solution and absor-
bance was read at 405 nm by automated plate-reader
(Tecan, Crailsheim, Germany). Serum TIMP-1 levels
above 454 ng/mL were regarded as elevated as pre-
viously described to be of relevance [7].
Quantitative analysis of serum CAIX level
CAIX was also quantified by a commercially available
ELISA (Siemens Healthcare Diagnostics, Tarrytown, NY,
USA). Serum samples and controls were diluted 1:2
with sample diluting buffer (containing bovine serum
albumin, mouse IgG, buffer salts, and 0.09% sodium
azide). One hundred microliters of the standards, of
diluted control samples, and of diluted serum samples
were dispensed into the wells of a 96-well plate (coated
with the monoclonal capture antibody) and incubated
for two hours at room temperature on a shaker at 800
rpm. Wells were washed, and 100 μlo ft h ed e t e c t i o n
antibody (containing biotinylated anti-CAIX antibody)
was added. The plates were incubated for 30 minutes at
room temperature, washed, and then further incubated
with 100 μl of a streptavidin horseradish peroxidase
conjugate for 30 minutes at room temperature. After
Table 1 Patients’ characteristics
Total CTC
positive
in
%
P
value
Overall 245 122 50%
ER status 244 122 50 0.26
Negative 74 33 45
Positive 170 89 52
PR status 244 122 50 0.51
Negative 99 47 48
Positive 145 75 52
HER2 status 245 122 123 0.15
Negative
1 138 76 55
Positive
2 75 31 41
Unknown
3 32 15 47
Metastatic site 245 122 50 0.07
Visceral 96 39 41
Bone 35 14 40
Both 114 69 61
Extent of metastatic
disease
245 122 50 0.03
One site 84 34 41
Multiple sites 161 88 55
Therapeutic setting 244 122 50
1st-line 94 48 51 0.48
2nd-line 64 28 44
3rd-line or more 86 46 54
CAIX 245 (253)
4
122 50
≤506 ng/ml 157 (163) 65 41 0.00
> 506 ng/ml 88 (90) 57 65
TIMP-1 245 (253)
4
122 50
≤454 ng/ml 179 (183) 77 43 0.00
> 454 ng/ml 66 (70) 45 68
1 Immunohistochemistry score: 0/+1 or fluorescence in situ hybridization
negative,
2 ICH score: +3 or fluorescence in situ hybridization positive
3 not determined or ICH score +2 and fluorescence in situ hybridization not
performed
4 in 9 patients CTC could not be determined
CAIX, carbonic anhydrase IX; CTC, circulating tumor cell; ER, estrogen receptor;
HER, human epidermal growth factor receptor; PR, progesterone receptor;
TIMP, tissue inhibitor of metalloproteinase.
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substrate) was added for 30 minutes at room tempera-
ture. The reaction was stopped with 100 μl of 2.5 N sul-
phuric acid and absorbance was read at 450 nm by an
automated plate reader (Tecan, Crailsheim, Germany).
The CAIX concentration was estimated from the stan-
dard curve. A value above 506 ng/mL was regarded as
elevated (mean of a age matched control + two standard
deviations) [24].
The TIMP-1 and CAIX concentrations were estimated
from the standard curve. Each sample, standard and
control were analyzed in duplicate. Inter-assay and
intra-assay coefficients of variation for both serum
assays were less than 10%.
Statistical analysis
Primary endpoint of the analysis described here was
the impact of TIMP-1 and CAIX alone and of each
marker in correlation to the presence of CTC. The
study was performed in accordance with REMARK cri-
teria [26,27]. Relations between categorical variables
were investigated using contingency tables. In case of
independent data, Fisher’se x a c tt e s tw a su s e dt oe v a l u -
ate the relation, whereby P values less than 0.05 indi-
cate statistical significance. When paired data were
considered in terms of assessing the reliability of test
results of the methods, agreement and consistency
were regarded via Cohen’s kappa and McNemar-test,
respectively. The four groups of patients (elevated/non-
elevated CTC and serum markers) were compared
using the log-rank test to evaluate whether there is a
difference in survival. In addition we have also tested
for comparing the marker positivity within CTC nega-
tive and CTC positive patients. Progression-free survi-
val (PFS) was defined as the time elapsed between
blood draw time point and disease progression. Overall
survival (OS) was defined as the time elapsed between
blood draw time point and patient’sd e a t h .T h e
Kaplan-Meier curves were compared using log-rank
test. Factors which have been of prognostic significance
in the univariate analysis were included in a multivari-
ate analysis using the Cox regression model. Statistical
analysis was performed using SPSS version 18.
Results
Detection rate of CTC and correlation with clinical
parameters
Five or more CTC were detected in 122 of 245 evaluable
patients (49.8%) and 180 patients (74%) had one or
more CTC. Elevated CTC levels of 5 CTC/7.5 mL or
more were only associated with the extend of metastatic
disease, and elevated TIMP-1 and CAIX levels. The
characteristics of patients and correlations with CTC
detection are shown in Table 1.
Serum levels of TIMP-1 and correlation with progression
free and overall survival
Of 253 metastatic patients, 70 (28%) had elevated serum
TIMP-1 levels above 454 ng/mL. Patients with elevated
TIMP-1 levels were more likely to have multiple metas-
tases (P < 0.05) located in bone and visceral organs (P <
0.01) and had more lines of previous therapy (P <0 . 0 1 ) .
No other correlations with clinicopathological factors
could be observed (data not shown).
Median PFS was 7.2 months in patients with elevated
TIMP-1 versus 11.4 months in those with non-elevated
levels (P < 0.01). OS was 19.1 months vs. 11.5 months
(P < 0.01). PFS and OS rates are listed in Table 2.
Serum levels of CAIX and correlation with progression
free and overall survival
Serum CAIX was elevated above 506 ng/mL in 90 (35%)
patients. Elevated CAIX levels were only correlated with
line of therapies (P < 0.01). Patients with elevated
CAIX-levels were more likely to have visceral
metastases.
Median PFS was 7.5 month in patients with elevated
CAIX versus 11.7 months in those with non-elevated
levels (P = 0.001). OS was 13.4 months vs. 19.1 months
(P < 0.01, see Table 2).
Elevated levels of both CAIX and TIMP-1 were seen
in 18% of patients (Figure 1; Table 2 and 3). When both
serum markers were non-elevated the median PFS was
12.4 and OS 20.1 months compared with 7.0 and 11.1
Table 2 Mean survival in correlation to CTC positivity,
TIMP-1 and CAIX levels
PFS in
months
P
value
OS in
months
P
value
CTC
< 5 cells 10.9 (9.4-12.5) 0.118 20.1 (18.8-
21.5)
< 0.01
≥ 5 cells 9.3 (7.8-10.9) 14.0 (12.8-
21.5)
TIMP-1
Non elevated 11.4 (10.1-12.7) < 0.01 19.1 (18.0-
20.3)
< 0.01
Elevated 7.2 (5.6-8.9) 11.5 (9.4-13.6)
CAIX
Non elevated 11.7 (10.3-13.1) < 0.01 19.1 (17.8-
20.4)
< 0.01
Elevated 7.5 (6.0-9.0) 13.4 (11.4-
15.4)
TIMP-1/CAIX
Both non-
elevated
12.4 (10.9-13.9) < 0.01 20.1 (18.8-
21.3)
< 0.01
Both elevated 7.0 (5.0-9.0) 11.1(8.5-13.6)
CAIX, carbonic anhydrase IX; CTC, circulating tumor cell; OS, overall survival;
PFS, progression-free survival; TIMP, tissue inhibitor of metalloproteinase.
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elevated.
Correlation of CTC detection to serum levels of TIMP-1
and CAIX
In patients with five or more CTC, serum levels were
above the cut-off for CAIX in 47% vs. 25% in those with
less than five CTC (P = 0.01). For TIMP-1, 37% patients
with five or more CTC had elevated serum levels in con-
trast to 17% with less than five CTC (P = 0.01). Correla-
tion between both serum markers and CTC status is
illustrated in Figure 1 and summarized in Tables 2 and 3.
Correlation of CTC detection in combination to serum
levels of TIMP-1 and CA IX with progression free and
overall survival
Among patients with less than 5 CTC/7.5 mL, those
individuals with non-elevated TIMP-1 had a median
PFS of 12.3 months compared with only 4.4 months
with elevated TIMP-1 levels. OS was 21.4 months with
non-elevated but only 12.0 months with elevated TIMP-
1. When five or more CTC were detected, patients with
non-elevated TIMP-1 concentrations had a median PFS
o f9 . 5m o n t h sv s .8 . 5m o n t h sw i t he l e v a t e dl e v e l s .T h e
OS in the group with five or more CTC non-elevated
TIMP-1 was 15.5 months vs. 12.0 months with elevated
TIMP. No difference in OS was observed between
patients with elevated TIMP-1 irrespective of CTC
detection (Figure 2 and Table 4).
Among patients with less than five CTC, those indivi-
duals with non-elevated CAIX had a median PFS of 11.6
months compared with 8.1 months with elevated CAIX.
OS was 21.3 months with non-elevated and 15.9 months
with elevated CAIX. When five or more CTC were
detected, patients with non-elevated CAIX had a median
PFS of 11.0 months versus 8.5 months with elevated
levels. The OS in the CTC group with less than five
CTC and non-elevated CAIX was 21.3 months vs. 15.9
months with elevated CAIX. In patients with five or
more CTC, OS was 16.2 months with non-elevated and
11.8 months with elevated CAIX (Figure 3 and Table 4).
Multivariate analysis
To evaluate the additional prognostic value of CAIX and
TIMP-1, a multivariate analysis was performed for OS
and PFS including the clinicopathological factors shown.
For OS, only CTC, line of therapy and CAIX revealed to
be independent prognostic factors. For PFS, only estro-
gen receptor, number of metastatic sites, and line of
therapy were independent factors. Results of univariate
and multivariate correlations are summarized in Table 5.
Discussion
Insights into the biology of the metastatic potential of
breast cancer cells are of relevance for several reasons.
One clinical aspect is the identification of patients with
more aggressive tumors that might benefit from more
intense therapy. Another important reason is the need
for an improved understanding of mechanisms leading
to hematogenous tumor cell dissemination. This is of
potential consequence for the development of new ther-
apeutic approaches. Blood is often preferred over tumor
tissue as it is easy to obtain. Also, repeated sampling is
possible, which allows the use of markers for monitoring
patients during the course of their disease. Thus, we
examined the two serum factors TIMP-1 and CAIX and
also investigated a correlation to the presence of CTC,
which is a “real time” parameter of tumor cell
dissemination.
Protein levels of TIMP-1 in tumor tissue are asso-
ciated with prognosis and therapy response in patients
with primary breast cancer [16-18,28] and with response
to chemotherapy [29]. Schrohl and colleagues were able
ǻ CTC positive
• CTC negative
Figure 1 Correlation between TIMP-levels (ng/ml) and CAIX
levels (ng/ml) subdivided after presence of CTC. CAIX, carbonic
anhydrase IX; CTC, circulating tumor cell; TIMP, tissue inhibitor of
metalloproteinase.
Table 3 Serum markers and CTC levels in metastatic
breast cancer patients
CAIX/TIMP-1 n (100%) CTC < 5 cells CTC > = 5 cells
Total 245 (100%) 123 (100%) 122 (100%)
Both non-elevated 135 (55%) 83 (68%) 52 (43%)
TIMP-1 elevated 66 (27%) 21 (17%) 45 (37%)
CAIX elevated 88 (36%) 31 (25%) 57 (47%)
Both elevated 44 (18%) 12 (10%) 32 (26%)
CAIX, carbonic anhydrase IX; CTC, circulating tumor cell; TIMP, tissue inhibitor
of metalloproteinase.
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also have a negative impact in the metastatic situation
indicating that TIMP-1 has a general impact on tumor
biology [29]. In an experimental study, also a role of
TIMP-1 for chemoresistance was described [30]. It was
recently shown in a prospective study that levels of
TIMP-1 in plasma and serum obtained preoperatively
from patients with primary breast cancer are associated
with prognosis [31] whereas plasma levels at the time of
primary surgery are not correlated with tissue concen-
trations [32]. Our results support the idea that also
serum TIMP-1 levels reflect an enhanced ability of
tumor tissues (including metastatic sites) to release cells
into the circulation. In our patient cohort, higher TIMP-
1 levels are associated with shorter PFS and OS in uni-
variate analysis, supporting the biologic relevance of this
factor. However, we cannot provide experimental evi-
dence for a direct role of TIMP-1 in the release of CTC
into the circulation. Rather than being involved in
tumor cell release, TIMP-1 might stabilize released cells
by inhibiting apoptosis through activation of survival
pathways either by inhibition of MMPs or independently
of MMPs. Furthermore, TIMP-1 protects tumor cells
from chemotherapy-induced apoptosis [10-12]. In addi-
tion, TIMP-1 is expressed in a variety of cell types,
including tumor cells and stromal cells and detectable
in most tissues and in body fluids. It is also expressed
by monocytes and macrophages and all these cells
might contribute to high TIMP-1 concentrations in
tumor tissue. Transcriptional analysis in colorectal can-
cer revealed that the expression of TIMP-1 in fibroblasts
is even higher than that in tumor cells [33]. TIMP-1
protein expression was also high in stromal cells closest
a) b)
__ CTC neg. and TIMP-1 nonelevated
..... both elevated
___ only CTC positive 
only TIMP-1 elevated ..... only TIMP-1 elevated
CTC neg and TIMP-1 nonelevated __ CTC neg. and TIMP 1 nonelevated
..... both elevated
___ only CTC positive 
..... only TIMP-1 elevated
Figure 2 Correlation between CTC detection, TIMP-1 and patient outcome. (a) Progression-free survival. (b) Overall survival of metastatic
breast cancer patients based on CTC positivity (≥ 5 CTC) and TIMP-1 serum levels. CTC, circulating tumor cell; TIMP, tissue inhibitor of
metalloproteinase.
Table 4 Mean survival based on CTC positivity, TIMP-1
and CAIX levels
PFS in months P value OS in months P value
CTC negative < 0.01
1 < 0.01
1
TIMP-1
Non elevated 12.3(10.6-14.1) < 0.01
2 21.4 (20.3-22.6) < 0.01
Elevated 4.4 (2.8-6.0) 12.0 (8.2-15.7)
CTC positive
TIMP-1
Non elevated 9.5 (7.6-11.4) 0.81 15.5 (13.3-17.7) 0.151
Elevated 8.5 (6.2-10.8) 12.0 (9.4-14.6)
CTC negative < 0.01
1 < 0.01
1
CAIX
Non elevated 11.6 (9.8-13.5) 0.06 21.3 (20.0-22.6) < 0.01
Elevated 8.1 (5.6-10.6) 15.9 (12.8-19.0)
CTC positive
CAIX
Non elevated 11.0(8.7-13.1) < 0.05 16.2 (14.0-18.4) < 0.05
Elevated 7.1(5.2-9.0) 11.8 (9.5-14.1)
1P value for comparing differences between all four groups,
2comparing
survival differences for comparing marker positivity within CTC negative and
positive patients
CAIX, carbonic anhydrase IX; CTC, circulating tumor cell; OS, overall survival;
PFS, progression-free survival; TIMP, tissue inhibitor of metalloproteinase.
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serum might be derived from different cell types (meta-
static tumor cells, surrounding stromal cells, infiltrating
macrophages, monocytes and others) making analysis of
rare single cells for TIMP-1 difficult. Moreover, CTC
were detected with the CellSearch system and the only
free fluorescence channel for further characterization of
CTC already was occupied for HER2 detection in our
study. Furthermore, tumor tissue from metastatic sites
was not available for further analysis in most cases.
a) b)
__ CTC neg. and CAIX nonelevated
..... both elevated
___ only CTC positive 
..... only CAIX elevated
__ CTC neg. and CAIX nonelevated
..... both elevated
only CTC positive ___ only CTC positive
..... only CAIX elevated
Figure 3 Correlation between CTC detection, CAIX and patient outcome. (a) Progression-free survival. (b) Overall survival of metastatic
breast cancer patients based on CTC positivity (≥ 5 CTC) and CAIX serum levels. CAIX, carbonic anhydrase IX; CTC, circulating tumor cell.
Table 5 Univariate and multivariate anlaysis for PFS and OS
PFS Univariate P
value
Multivariate P
value
HR 95% CI OS Univariate P
value
Multivariate P
value
HR 95% CI
CAIX-levels
Elevated vs. non elevated
< 0.01 0.06 1.38 0.99 -
1.92
< 0.01 .04 1.68 1.02 -
2.77
TIMP levels
Elevated vs. non elevated
< 0.01 0.21 1.26 0.88 -
1.80
< 0.01 .09 1.55 0.93 -
2.58
Therapy line
>1
st line vs. 1
st line
< 0.01 < 0.01 2.61 1.84 -
3.70
< 0.01 < 0.01 2.61 1.45 -
4.70
Grading
3 vs. 1/2
0.49 - - - 0.41 - - -
Menopusal status
Premeno vs. postmeno
0.06 - - - 0.49 - - -
ER status
Negative vs. positive
0.03 0.01 1.51 1.90 -
2.10
0.21 - - -
PR status
Negative vs. positive
0.07 - - - 0.57 - - -
HER2 status
Negative vs. positive
0.17 - - - 0.40 - - -
Number of metastatic
sites
Multiple vs. single
< 0.01 0.02 1.52 1.08 -
2.15
< 0.01 0.27 1.37 0.78 -
2.40
CTC count
≥ 5 cells vs. < 5 cells
0.12 - - - < 0.01 < 0.01 2.48 1.46-4.36
CAIX, carbonic anhydrase IX; CI, confidence interval; CTC, circulating tumor cell; ER, estrogen receptor; HER, human epidermal growth factor receptor; HR, hazard
ratio; OS, overall survival; PFS, progression-free survival; PR, progesterone receptor; TIMP, tissue inhibitor of metalloproteinase.
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expression of TIMP-1 and/or CAIX in the tumor tissue
or on CTC.
The fact that for TIMP-1 a relevant difference in PFS
was observed only in patients with less than five CTC
and the OS difference between patients with elevated
and non-elevated TIMP-1 was also larger in patients
with low CTC numbers could indicate that serum
TIMP-1 is especially relevant in patients without the
detection of elevated CTC counts. This might open a
clinical perspective for this marker also in the context of
CTC measurements because even in metastatic breast
cancer a relevant portion has CTC counts below the
widely established cut off of five or more CTC in 7.5
mL blood. In patients with elevated TIMP-1, OS did not
differ between patients with CTC findings above and
below the cut off. Therefore, TIMP-1 does not seem to
add prognostic relevance in CTC-positive patients. Cur-
rently, we do not have an explanation for the observa-
tion that patients with elevated TIMP-1 and less than
five CTC/7.5 ml had the shortest PFS (Figure 2 and
Table 4). In addition, it is not possible to exclude that at
least some patients with elevated TIMP-1 levels who are
detected to be “CTC-negative” in the CellSearch assay
represent a subpopulation of patients with still undetect-
able CTC that have lost their epithelial characteristics in
the course of epithelial-mesenchymal transition [35].
A generally accepted normal level of TIMP-1 serum
concentration was not defined so far. Our study was not
designed to validate cut-off values for these markers.
Lipton et al. applied a cut-off of 454 ng/mL (95% of the
control group) when they used control group of 49
healthy postmenopausal women to derive the serum
TIMP-1 cut-off with the same assay as used in our
study [7].
A l t e r e dg l y c o l y s i si sam a in metabolic feature of
malignant cells. Combined with decreased oxidative
phosphorylation it can result in acidification of the
extracellular space [36,37]. Transcription factors of the
glycolytic pathway also influence cell proliferation and
differentiation; disordered glycolysis and acidic milieu
were therefore proposed to play a major role in the
complex multistep process of carcinogenesis [37-41].
One of the enzymes contributing to acidification of the
extracellular space is CAIX. It is a transmembrane zinc
enzyme catalyzing the hydration of carbon dioxide [42].
CAIX is strongly induced by hypoxia via activation of
transcriptional factors such as HIF-1 [43]. CAIX is over-
expressed in a variety of solid tumors with different
results for its potential role in gynecologic cancers and
breast cancer [44-48]. The inhibition of this enzyme is a
potiential therapeutic approach [49-51]. In renal cell
cancer, overexpression of CAIX is common and the pos-
sible role of CAIX targeting antibodies (WX-G250,
Rencarex
®) is currently being evaluated in phase III
trials for this entity [52]. There is some information on
serum values in renal cell cancer patients showing sig-
nificantly higher values in patients with metastatic dis-
ease than in patients with localized cancer. Furthermore,
renal cell cancer patients with high serum CAIX before
surgery were at significantly higher risk for disease
recurrence than those with low preoperative values [23].
The role of serum CAIX in breast cancer has not been
determined. As hypoxia is postulated to be associated
with hematogenous tumor cell dissemination in breast
cancer [53], we examined this factor in correlation to
the detection of CTC. It appears that CAIX alone has
prognostic significance in both CTC-negative and CTC-
positive groups and we provide to our knowledge the
first evidence for a prognostic relevance of serum CAIX.
This is of potential clinical relevance for the application
of new therapeutic approaches inhibiting angiogenesis
or directly CAIX.
Moreover, our findings show an association between
elevated CAIX serum levels and the presence of CTC
which also supports the experimental findings that indi-
cate an association between hypoxia and release of
tumor cells into the circulation. Our observations also
could indicate that CAIX in contrast to TIMP-1 has
prognostic relevance in patients with elevated and non-
elevated CTC numbers (Figure 3 and Table 4). However,
we cannot definitely explain the correlation we observed
because the cellular origin of serum CAIX in our
patients is not clear. Elevated levels of both CAIX and
TIMP-1 were seen in 18% of patients (Figure 1; Table
2). However, in the overall cohort no relevant improve-
ment for the prognostic information concerning PFS
and OS was observed. This does not deliver the ratio-
nale for a combined use as prognostic markers.
The lack of correlation between CTC detection and
PFS in multivariate analysis in our cohort might be due
to different treatments, therapeutic settings (1
st line, 2
nd
line, 3
rd line and more), metastatic sites, and by slightly
different response monitoring according to the institu-
tional standards of the participating Breast Cancer Cen-
ters. For example, in the currently most cited
publication using the CellSearch System also applied in
our study [3], 47% of patients were starting their first
line of therapy whereas in our cohort the rate was only
38%. In addition, the use of targeted therapies (trastuzu-
mab and lapatinib for HER2-positive and bevacizumab
for HER2-negative patients) might change the prognos-
tic relevance of CTC detection with respect to PFS as
the end point. Similarly to other studies, we did not
observe a correlation between CTC detection and estro-
gen receptor/progesterone receptor and HER2 status of
the corresponding primary tumors [3]. The fact that we
did not detect a significantly higher number of CTC-
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other sites of metastasis is not in line with some other
findings, but might be explained by the relatively small
number of patients only with bone metastasis (n = 35)
enrolled in our patient study. Taken together, this lack
of standardized treatment is a potential drawback of the
study However, the strength of our study is the prospec-
tive and multicenter setting and the analysis of biomar-
kers blinded for clinical data.
Conclusions
This study demonstrates with a prospective design that
serum TIMP-1 and CAIX have prognostic impact in
metastatic breast cancer and elevated serum levels of
these invasion markers are associated with the presence
of CTC-positivity. The mechanisms that lead to tumor
cell dissemination from primary tumors or metastases
have not been recognized in detail yet. To find out
whether TIMP-1 and CAIX are involved in this process,
for example by loosening cell adhesion, changing pH
conditions or prolongation of CTC survival has to be
further investigated in experimental model systems.
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